Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis

By Kelly Cloonan

Bristol Myers Squibb said a trial evaluating its admilparant treatment in adults with idiopathic pulmonary fibrosis met its primary endpoint.

The phase 3 trial evaluated two dose levels of admilparant taken twice daily for 52 weeks against a placebo. The 60-milligram dose demonstrated a statistically significant improvement compared to placebo in absolute change in forced vital capacity from baseline, while the 120-milligram dose slowed the decline of FVC but was not statistically significant, the company said Monday.

Bristol Myers Squibb said the findings reinforce the potential of admilparant as a clinically meaningful treatment for idiopathic pulmonary fibrosis, a type of pulmonary fibrosis with no identifiable cause that affects about 1.4 million globally.

Pulmonary fibrosis is a chronic and life-threatening lung disease that occurs when lung tissue becomes irreversibly damaged and scarred. It has a median survival time of three to five years following diagnosis and a five-year survival rate of about 45%, with few new treatments approved in recent years.

Bristol Myers Squibb said it would complete a comprehensive evaluation of the trial data and work with health authorities to support planned regulatory submissions. It expects to present detailed results from the trial at a future medical meeting.

Admilparant is also being studied in a Phase 3 trial for progressive pulmonary fibrosis, with topline results anticipated in early 2027.

The stock gained 5.8%, to $62.57, in premarket trading Monday.

Bristol Myers Squibb also separately reported positive results from an interim analysis of a Phase 3 trial for RYZ101 in certain patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 12, 2026 07:43 ET (11:43 GMT)